Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 11

Mathematical modelling of synergistic triple-antibiotic therapy against carbapenem-resistant at clinically achievable concentrations Open Access

Abstract

Carbapenem-resistant (CRAB) represents a critical healthcare threat with limited treatment options, particularly challenging in Southeast Asia where resistance rates exceed 65%.

Current synergy testing methods are labour-intensive and poorly standardized, limiting their clinical application. We hypothesize that synergistic interactions between antibiotics follow predictable mathematical patterns derivable from separate MIC determinations for each antibiotic.

To evaluate the efficacy of colistin-meropenem-ampicillin/sulbactam combinations at standard dosages and develop a predictive mathematical model for synergistic interactions against CRAB.

A cross-sectional study was conducted using 61 CRAB clinical isolates from a Vietnamese tertiary hospital. MICs were determined using broth microdilution, and synergy was assessed via checkerboard assays. Mathematical models were developed to predict fractional inhibitory concentration (FIC) values from separate MIC determinations for each antibiotic.

All isolates demonstrated high-level meropenem resistance (MICs 32-≥128 µg ml) and ampicillin/sulbactam resistance (98.4% with MICs≥64/32 µg ml) but remained intermediate to colistin (MICs 0.0625–0.25 µg ml). The triple combination achieved 100% synergy at standard ampicillin/sulbactam doses (8/4 µg ml). Our log-transformed power model accurately predicted synergistic interactions (²=0.928) using the equation log(FIC) = −2.52+(−1.02) × 1/√Mero+0.43×1/√Col+4.32×1/√As.

The triple combination achieves universal synergy at standard dosages, potentially reducing toxicity risks. Our mathematical model enables rapid prediction of effective combinations from routine susceptibility tests, offering a transformative approach to optimizing therapy against multidrug-resistant pathogens.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Acinetobacter baumannii , antibiotic synergy , carbapenem resistance , mathematical modelling and triple combination therapy
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.002086
2025-11-05
2025-12-16

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/11/jmm002086.html?itemId=/content/journal/jmm/10.1099/jmm.0.002086&mimeType=html&fmt=ahah

References

  1. WHO Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development; 2017 https://www.quotidianosanita.it/allegati/allegato4135670.pdf
  2. Chung DR, Song J-H, Kim SH, Thamlikitkul V, Huang S-G et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184:1409–1417 [View Article]
     [Google Scholar]
  3. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother 2013; 57:6270–6275 [View Article]
     [Google Scholar]
  4. Teerawattanapong N, Panich P, Kulpokin D, Na Ranong S, Kongpakwattana K et al. A systematic review of the burden of multidrug-resistant healthcare-associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol 2018; 39:525–533 [View Article] [PubMed]
     [Google Scholar]
  5. Le T, Thanh Nga TT, Minoru A, Kirikae T. Ventilation associated pneumonia caused by Acinetobacter Baumanii at a tertiary hospital in Vietnam: clinical and molecular patterns. Am J Infect Control 2012; 40:e53 [View Article]
     [Google Scholar]
  6. Nhu NTK, Lan NPH, Campbell JI, Parry CM, Thompson C et al. Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. J Med Microbiol 2014; 63:1386–1394 [View Article] [PubMed]
     [Google Scholar]
  7. Vu TVD, Choisy M, Do TTN, Nguyen VMH, Campbell JI et al. Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017. Antimicrob Resist Infect Control 2021; 10:78 [View Article] [PubMed]
     [Google Scholar]
  8. Diep DTH, Tuan HM, Ngoc KM, Vinh C, Dung TTN et al. The clinical features and genomic epidemiology of carbapenem-resistant Acinetobacter baumannii infections at a tertiary hospital in Vietnam. J Glob Antimicrob Resist 2023; 33:267–275 [View Article] [PubMed]
     [Google Scholar]
  9. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis 2024ciae403 [View Article] [PubMed]
     [Google Scholar]
  10. Penwell WF, Shapiro AB, Giacobbe RA, Gu R-F, Gao N et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 2015; 59:1680–1689 [View Article]
     [Google Scholar]
  11. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56:432–436 [View Article] [PubMed]
     [Google Scholar]
  12. Suzuki T, Sugiyama E, Nozawa K, Tajima M, Takahashi K et al. Effects of dosing frequency on the clinical efficacy of ampicillin/sulbactam in Japanese elderly patients with pneumonia: a single‐center retrospective observational study. Pharmacol Res Perspect 2021; 9:e00746 [View Article]
     [Google Scholar]
  13. Tan TY, Lim TP, Lee WHL, Sasikala S, Hsu LY et al. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011; 55:436–438 [View Article] [PubMed]
     [Google Scholar]
  14. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an “old” class of antibiotics. Future Microbiol 2013; 8:711–724 [View Article] [PubMed]
     [Google Scholar]
  15. Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother 2017; 61:e01268-16 [View Article] [PubMed]
     [Google Scholar]
  16. Garcia LS. Clinical Microbiology Procedures Handbook American Society for Microbiology Press; 2010 [View Article]
     [Google Scholar]
  17. Stefaniuk E, Baraniak A, Gniadkowski M, Hryniewicz W. Evaluation of the BD Phoenix automated identification and susceptibility testing system in clinical microbiology laboratory practice. Eur J Clin Microbiol Infect Dis 2003; 22:479–485 [View Article] [PubMed]
     [Google Scholar]
  18. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281 [View Article] [PubMed]
     [Google Scholar]
  19. CLSI Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100, 33rd ed Clinical and Laboratory Standards Institute; 2023
     [Google Scholar]
  20. Leber AL. Clinical Microbiology Procedures Handbook ASM Press; 2016 [View Article]
     [Google Scholar]
  21. Jiang Z, He X, Li J. Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis. Infect Drug Resist 2018; 11:1083–1095 [View Article] [PubMed]
     [Google Scholar]
  22. Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY et al. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 2011; 60:605–611 [View Article] [PubMed]
     [Google Scholar]
  23. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538–582 [View Article] [PubMed]
     [Google Scholar]
  24. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23:332–339 [View Article] [PubMed]
     [Google Scholar]
  25. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692–699 [View Article] [PubMed]
     [Google Scholar]
  26. Chong SJ, Ahmed S, Tay JM, Song C, Tan TT. 5 year analysis of bacteriology culture in a tropical burns ICU. Burns 2011; 37:1349–1353 [View Article] [PubMed]
     [Google Scholar]
  27. Guerrero DM, Perez F, Conger NG, Solomkin JS, Adams MD et al. Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease. Surg Infect 2010; 11:49–57 [View Article] [PubMed]
     [Google Scholar]
  28. Vu TVD, Choisy M, Do TTN, Nguyen VMH, Campbell JI et al. Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016–2017. Antimicrob Resist Infect Control 2021; 10:78 [View Article]
     [Google Scholar]
  29. Bostanghadiri N, Narimisa N, Mirshekar M, Dadgar-Zankbar L, Taki E et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2024; 13:24 [View Article]
     [Google Scholar]
  30. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60:1295–1303 [View Article] [PubMed]
     [Google Scholar]
  31. Gao L, Lyu Y, Li Y. Trends in drug resistance of Acinetobacter baumannii over a 10-year period: nationwide data from the China Surveillance of Antimicrobial Resistance Program. Chin Med J 2017; 130:659–664 [View Article] [PubMed]
     [Google Scholar]
  32. Aksoy MD, Çavuşlu Ş, Tuğrul HM. Investigation of metallo-beta-lactamases and oxacillinases in carbapenem-resistant Acinetobacter baumannii strains isolated from inpatients. Balkan Med J 2015; 32:79–83 [View Article] [PubMed]
     [Google Scholar]
  33. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10–39 [View Article]
     [Google Scholar]
  34. Huang C, Chen I, Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a meta-analysis. JCM 2022; 11:3239 [View Article]
     [Google Scholar]
  35. Wang F-J, Lyu Y, Liu Z-H, Li Y, Cui L-Q. In vitro activity of different antibacterial agents in combination with each other against multidrug-resistant Acinetobacter baumannii. Chin Med J 2016; 129:2388–2389 [View Article]
     [Google Scholar]
  36. Ramadan RA, Gebriel MG, Kadry HM, Mosallem A. Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations. Infect Drug Resist 2018; 11:1261–1269 [View Article]
     [Google Scholar]
  37. Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2013; 65:1053–1090 [View Article] [PubMed]
     [Google Scholar]
  38. Patrick M, Kilpatrick C, Storr J, Gon G, Huynh T et al. Environmental cleaning barriers and mitigation measures identified through two initiatives in four countries, 2018-2023: a commentary. Antimicrob Resist Infect Control 2024; 13:134 [View Article] [PubMed]
     [Google Scholar]
  39. Huynh MT, Jusselme MD, Van Pham H, Nguyen TD, Chau MQ. Characterization of phenotypic and genotypic traits of Klebsiella pneumoniae strains resistant to 3rd generation cephalosporins in hospital settings: a case study in Ho Chi Minh City, Vietnam. Mol Biol Rep 2025; 52:396 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.002086
Loading
Mathematical modelling of synergistic triple-antibiotic therapy against carbapenem-resistant Acinetobacter baumannii at clinically achievable concentrations
J. Med. Microbiol. 74, 002086 (2025); https://doi.org/10.1099/jmm.0.002086
/content/journal/jmm/10.1099/jmm.0.002086
/content/journal/jmm/10.1099/jmm.0.002086
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error